Rasitrio

RSS

Withdrawn

This medicine's authorisation has been withdrawn

aliskiren / amlodipine / hydrochlorothiazide
MedicineHumanWithdrawn

Estonian is available via eTranslation, the European Commission's machine translation service.

Translate to Estonian | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

The marketing authorisation for Rasitrio has been withdrawn at the request of the marketing authorisation holder.

български (BG) (625.38 KB - PDF)

Vaata

español (ES) (543.72 KB - PDF)

Vaata

čeština (CS) (670.39 KB - PDF)

Vaata

dansk (DA) (543.79 KB - PDF)

Vaata

Deutsch (DE) (546.13 KB - PDF)

Vaata

eesti (ET) (544.01 KB - PDF)

Vaata

ελληνικά (EL) (633.13 KB - PDF)

Vaata

français (FR) (546 KB - PDF)

Vaata

italiano (IT) (542.82 KB - PDF)

Vaata

latviešu (LV) (608.53 KB - PDF)

Vaata

lietuvių (LT) (567.61 KB - PDF)

Vaata

magyar (HU) (600.79 KB - PDF)

Vaata

Malti (MT) (612.74 KB - PDF)

Vaata

Nederlands (NL) (543.74 KB - PDF)

Vaata

polski (PL) (1.09 MB - PDF)

Vaata

português (PT) (543.7 KB - PDF)

Vaata

română (RO) (567.9 KB - PDF)

Vaata

slovenčina (SK) (609.79 KB - PDF)

Vaata

slovenščina (SL) (599.18 KB - PDF)

Vaata

suomi (FI) (544.93 KB - PDF)

Vaata

svenska (SV) (542.67 KB - PDF)

Vaata

Product information

български (BG) (10.89 MB - PDF)

Vaata

español (ES) (4.66 MB - PDF)

Vaata

čeština (CS) (8 MB - PDF)

Vaata

dansk (DA) (4.42 MB - PDF)

Vaata

Deutsch (DE) (4.78 MB - PDF)

Vaata

eesti (ET) (2.92 MB - PDF)

Vaata

ελληνικά (EL) (10.67 MB - PDF)

Vaata

français (FR) (5.2 MB - PDF)

Vaata

italiano (IT) (3.02 MB - PDF)

Vaata

latviešu (LV) (8.2 MB - PDF)

Vaata

lietuvių (LT) (5.02 MB - PDF)

Vaata

magyar (HU) (8.24 MB - PDF)

Vaata

Malti (MT) (8.6 MB - PDF)

Vaata

Nederlands (NL) (4.66 MB - PDF)

Vaata

polski (PL) (8.54 MB - PDF)

Vaata

português (PT) (4.6 MB - PDF)

Vaata

română (RO) (5.27 MB - PDF)

Vaata

slovenčina (SK) (8.17 MB - PDF)

Vaata

slovenščina (SL) (8.29 MB - PDF)

Vaata

suomi (FI) (4.65 MB - PDF)

Vaata

svenska (SV) (4.53 MB - PDF)

Vaata

Íslenska (IS) (4.53 MB - PDF)

Vaata

norsk (NO) (4.58 MB - PDF)

Vaata
Latest procedure affecting product information:IB/0015
03/10/2013
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (608.24 KB - PDF)

Vaata

español (ES) (497.14 KB - PDF)

Vaata

čeština (CS) (1 MB - PDF)

Vaata

dansk (DA) (496.37 KB - PDF)

Vaata

Deutsch (DE) (497.7 KB - PDF)

Vaata

eesti (ET) (496.69 KB - PDF)

Vaata

ελληνικά (EL) (610.98 KB - PDF)

Vaata

français (FR) (500.89 KB - PDF)

Vaata

italiano (IT) (497.22 KB - PDF)

Vaata

latviešu (LV) (580.69 KB - PDF)

Vaata

lietuvių (LT) (527.73 KB - PDF)

Vaata

magyar (HU) (590.84 KB - PDF)

Vaata

Malti (MT) (562.9 KB - PDF)

Vaata

Nederlands (NL) (496.21 KB - PDF)

Vaata

polski (PL) (1.02 MB - PDF)

Vaata

português (PT) (497.58 KB - PDF)

Vaata

română (RO) (527.11 KB - PDF)

Vaata

slovenčina (SK) (578.02 KB - PDF)

Vaata

suomi (FI) (496.74 KB - PDF)

Vaata

Íslenska (IS) (493.62 KB - PDF)

Vaata

norsk (NO) (490.07 KB - PDF)

Vaata

Product details

Name of medicine
Rasitrio
Active substance
  • aliskiren
  • amlodipine
  • hydrochlorothiazide
International non-proprietary name (INN) or common name
  • aliskiren
  • amlodipine
  • hydrochlorothiazide
Therapeutic area (MeSH)
Hypertension
Anatomical therapeutic chemical (ATC) code
C09XA54

Pharmacotherapeutic group

Cardiovascular system

Therapeutic indication

Rasitrio is indicated for the treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of aliskiren, amlodipine and hydrochlorothiazide given concurrently at the same dose level as in the combination.

Authorisation details

EMA product number
EMEA/H/C/002017
Marketing authorisation holder
Novartis Europharm Ltd.

Wimblehurst Road
Horsham
West Sussex
RH12 5AB
United Kingdom

Marketing authorisation issued
22/11/2011
Revision
1

Assessment history

This page was last updated on

Share this page